MANE vs MEDP
Veradermics, Incorporated vs Medpace — AI-powered side-by-side comparison
MANE
Veradermics, Incorporated
67
Buy
VS
| Metric | MANE | MEDP |
|---|
| AI Score |
67
|
64
|
| Price |
$111.00
|
$582.01
|
| P/E Ratio |
-69.90×
|
34.33×
|
| ROE |
57.8%
|
98.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
28.8%
|
| Debt / Equity |
0.00×
|
0.28×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
48.6
|
62.3
|
| Beta |
1.3492
|
1.151
|
| Expected Upside |
+6.7%
|
+4.4%
|
AI Committee View
Current Innellis committee reasoning for MANE versus MEDP.
MANE leads by 3 points.
MANE scores 67/100 (Buy) versus MEDP at 64/100 (Buy).
MANE Committee View
80% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 33.1 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 33.1 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical